Travere Therapeutics (TVTX) Shares Outstanding (Weighted Average) (2011 - 2026)

Travere Therapeutics has reported Shares Outstanding (Weighted Average) for 16 years, with the latest figure at $91.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.98% year-over-year to $91.9 million; the trailing twelve-month figure through Mar 2026 stood at $91.9 million (up 3.98% YoY), and the FY2025 full-year result was $89.2 million, up 13.09% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $91.9 million, up from $89.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $91.9 million in Q1 2026, with the low at $63.1 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $76.7 million across 5 years, with a median of $77.1 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) climbed 19.16% — and 2024, when it grew 1.93%.
• Travere Therapeutics' Shares Outstanding (Weighted Average) stood at $63.8 million in 2022, then grew by 16.48% to $74.3 million in 2023, then grew by 6.22% to $78.9 million in 2024, then increased by 13.09% to $89.2 million in 2025, then climbed by 2.98% to $91.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $91.9 million (Q1 2026), $89.2 million (Q4 2025), and $88.8 million (Q3 2025), per Business Quant data.